about
An epitope delivery system for use with recombinant mycobacteria.Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing glutathione S-transferase from Schistosoma haematobium.Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria.Molecular cloning and sequencing of the circumsporozoite protein gene from Plasmodium falciparum strain FCC-1/HN and expression of the gene in Mycobacteria.Rational live oral carrier vaccine design by mutating virulence-associated genes of Yersinia enterocoliticaMultidrug resistance following expression of the Escherichia coli marA gene in Mycobacterium smegmatis.Influence of mouse strain and vaccine viability on T-cell responses induced by Mycobacterium bovis bacillus Calmette-Guérin.Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen.The RipA and RipB Peptidoglycan Endopeptidases Are Individually Nonessential to Mycobacterium smegmatis.Establishment of a foreign antigen secretion system in mycobacteria.Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model.
P2860
Q33757525-BAA784D4-54DD-4A88-A2F5-F6D56E7D11E6Q33768306-803CD538-17BA-43CD-8E9E-3B229E68B7A6Q34006339-D9AD34E4-B8D2-4CC0-B5C6-8B43CEFDCA92Q36361980-8EBCAE27-FBF0-48D7-8956-BD8CCC4E7D22Q36364180-81DAB63F-A847-4167-8159-A1907932D6E0Q36708676-00E1C712-AF36-4EBC-9ABC-ACFD5FA2F533Q37427354-CDBAA546-5E3E-4AF8-98FE-533B86FE93D4Q39465759-BF850DD0-6973-4CFC-90CF-A33A47CE2B1BQ39512451-D194E8A0-7D85-472E-8234-ED2A8F4F1C90Q39566356-6F3B24DE-666F-4276-81A8-A090AB5E8A87Q39822079-5EA88F12-C1AB-488A-A2C2-330CB071C0C3Q39833195-08AA5267-3E5B-48D9-B7BB-935007778246Q40333845-F5BBD421-269E-4E41-924D-0F425C536D92Q40429250-DA8FFC7D-4E54-4555-88AB-1946455301C1Q43731754-0D9B2900-8825-44EC-8A5E-A1AB60130851
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Development of BCG as a recombinant vaccine vehicle.
@en
type
label
Development of BCG as a recombinant vaccine vehicle.
@en
prefLabel
Development of BCG as a recombinant vaccine vehicle.
@en
P2093
P1476
Development of BCG as a recombinant vaccine vehicle
@en
P2093
P304
P356
10.1007/978-3-642-74983-4_11
P50
P577
1990-01-01T00:00:00Z